Yasuyuki Arai

Yasuyuki Arai

Auto-generated profile, based on publicly available information

Yasuyuki Arai

Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
YAYasuyuki Arai
Yasuyuki Arai
KYKouhei Yamashita
Kouhei Yamashita
KMKiyomi Mizugishi
Kiyomi Mizugishi
TWTomohiro Watanabe
Tomohiro Watanabe
SSSoichiro Sakamoto
Soichiro Sakamoto
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a devastating complication of hematopoietic stem cell transplantation. TA-TMA likely represents the final stage of vascular endothelial injury; however, its pathophysiology is largely unknown, making clinical management difficult. Recently, the association of neutrophil extracellular traps (NETs) with the development of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome has been reported. Thus, we explored whether NETs are also relevant to the occurrence of TA-TMA. We retrospectively analyzed post-transplant trends of serum NET levels in 90 patients, 11 of whom developed TA-TMA. Relative to baseline (before the conditioning regimen), elevated serum NET levels either at 4 weeks after transplantation or as early as the day of transplantation were associated with significantly increased risk of TA-TMA. In contrast, thrombomodulin, a potential marker for TA-TMA, was not helpful to predict the occurrence of TA-TMA in our study. In addition, we directly detected glomerular deposition of NETs in 2 TA-TMA patients. Increased NET levels are a significant risk factor for TA-TMA, suggesting that NET level is a useful biomarker for TA-TMA.

1 January 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YAYasuyuki Arai
Yasuyuki Arai
YNYoko Nishinaka
Yoko Nishinaka
TAToshiyuki Arai
Toshiyuki Arai
MMMakiko Morita
Makiko Morita
KMKiyomi Mizugishi
Kiyomi Mizugishi
KYKouhei Yamashita
Kouhei Yamashita

1 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
NSNaoshi Sugimoto
Naoshi Sugimoto
JKJunya Kanda
Junya Kanda
SNSou Nakamura
Sou Nakamura
TKToshiyuki Kitano
Toshiyuki Kitano
MHMasakatsu Hishizawa
Masakatsu Hishizawa
KEKoji Eto
Koji Eto
Refractoriness to platelet transfusion is a major problem in a small group of patients, and large-scale manufacturing of clinical grade functional platelets ex vivo has remained an elusive goal. Sugimoto et al report on the results of the first clinical trial of an autologous transfusion of induced pluripotent stem cell (iPSC)-derived platelets in a patient who had severe aplastic anemia but no compatible platelet donor. Using methodology described in a complementary article in Blood Advances, the results provide proof-of-principle and illustrate the challenges to be faced in taking this approach further.

1 August 2015 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YAYasuyuki Arai
Yasuyuki Arai
KMKiyomi Mizugishi
Kiyomi Mizugishi
KNKazuhiko Nonomura
Kazuhiko Nonomura
KNKatsuki Naitoh
Katsuki Naitoh
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
KYKouhei Yamashita
Kouhei Yamashita

26 March 2014 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
TWT Watanabe
T Watanabe
NANaoki Asano
Naoki Asano
GMG Meng
G Meng
KYK Yamashita
K Yamashita
YAY Arai
Y Arai
WSWarren Strober
Warren Strober
It is well established that polymorphisms of the caspase activation and recruitment domain 15 (CARD15) gene, a major risk factor in Crohn’s disease (CD), lead to loss of nucleotide-binding oligomerization domain 2 (NOD2) function. However, a molecular explanation of how such loss of function leads to increased susceptibility to CD has remained unclear. In a previous study exploring this question, we reported that activation of NOD2 in human dendritic cells by its ligand, muramyl dipeptide (MDP), negatively regulates Toll-like receptor (TLR)-mediated inflammatory responses. Here we show that NOD2 activation results in increased interferon regulatory factor 4 (IRF4) expression and binding to tumor necrosis factor receptor associated factor 6 (TRAF6) and RICK (receptor interacting serine–threonine kinase). We then show that such binding leads to IRF4-mediated inhibition of Lys63-linked polyubiquitination of TRAF6 and RICK and thus to downregulation of nuclear factor (NF)-κB activation. Finally, we demonstrate that protection of mice from the development of experimental colitis by MDP or IRF4 administration is accompanied by similar IRF4-mediated effects on polyubiquitination of TRAF6 and RICK in colonic lamina propria mononuclear cells. These findings thus define a mechanism of NOD2-mediated regulation of innate immune responses to intestinal microflora that could explain the relation of CARD15 polymorphisms and resultant NOD2 dysfunction to CD.

1 October 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
YAYasuyuki Arai
Yasuyuki Arai
KYKouhei Yamashita
Kouhei Yamashita
KKKatsutoshi Kuriyama
Katsutoshi Kuriyama
MSMasahiro Shiokawa
Masahiro Shiokawa
YKYuzo Kodama
Yuzo Kodama
TWTomohiro Watanabe
Tomohiro Watanabe
The abnormal immune response accompanying IgG4-related autoimmune pancreatitis (AIP) is presently unclear. In this study, we examined the role of plasmacytoid dendritic cell (pDC) activation and IFN-α production in this disease as well as in a murine model of AIP (MRL/Mp mice treated with polyinosinic-polycytidylic acid). We found that the development of AIP in treated MRL/Mp mice occurred in parallel with pancreatic accumulation of pDCs producing IFN-α, and with pDC depletion and IFN-α-blocking studies, we showed that such accumulation was necessary for AIP induction. In addition, we found that the pancreas of treated MRL/Mp mice contained neutrophil extracellular traps (NETs) shown previously to stimulate pDCs to produce IFN-α. Consistent with these findings, we found that patients with IgG4-related AIP also exhibited pancreatic tissue localization of IFN-α–expressing pDCs and had significantly higher serum IFN-α levels than healthy controls. In addition, the inflamed pancreas of these patients but not controls also contained NETs that were shown to be capable of pDC activation. More importantly, patient pDCs cultured in the presence of NETs produced greatly increased levels of IFN-α and induced control B cells to produce IgG4 (but not IgG1) as compared with control pDCs. These data suggest that pDC activation and production of IFN-α is a major cause of murine AIP; in addition, the increased pDC production of IFN-α and its relation to IgG4 production observed in IgG4-related AIP suggest that this mechanism also plays a role in the human disease.